Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108.
about
Therapeutic options in peripheral T cell lymphomaAurora-A Kinase as a Promising Therapeutic Target in CancerRecent advances in the development of Aurora kinases inhibitors in hematological malignanciesNovel Targeted Agents in Hodgkin and Non-Hodgkin Lymphoma TherapyScientific Rationale Supporting the Clinical Development Strategy for the Investigational Aurora A Kinase Inhibitor Alisertib in CancerPhase I study of the aurora A kinase inhibitor alisertib with induction chemotherapy in patients with acute myeloid leukemia.A phase 2 study of alisertib (MLN8237) in recurrent or persistent uterine leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group study 0231D.Aurora kinases: novel therapy targets in cancersABCG2 impairs the activity of the aurora kinase inhibitor tozasertib but not of alisertibCell cycle proteins as promising targets in cancer therapyThe role of alisertib in treatment of peripheral T-cell lymphomas.Investigational drugs for T-cell lymphoma.The Aurora kinase inhibitors in cancer research and therapy.How I manage peripheral T-cell lymphoma, not otherwise specified and angioimmunoblastic T-cell lymphoma: current practice and a glimpse into the future.An update on the pharmacokinetics and pharmacodynamics of alisertib, a selective Aurora kinase A inhibitor.T-Cell Lymphoma: Recent Advances in Characterization and New Opportunities for Treatment.Clinical Development of Anti-mitotic Drugs in Cancer.An open-label, single-arm, phase 2 study of the Aurora kinase A inhibitor alisertib in patients with advanced urothelial cancer.Recent advances in understanding and managing T-cell lymphoma.Co-targeting aurora kinase with PD-L1 and PI3K abrogates immune checkpoint mediated proliferation in peripheral T-cell lymphoma: a novel therapeutic strategy.Polo-like-kinase 1 (PLK-1) and c-myc inhibition with the dual kinase-bromodomain inhibitor volasertib in aggressive lymphomas.A Review of New Findings in Adult T-cell Leukemia-Lymphoma: A Focus on Current and Emerging Treatment Strategies.Alisertib: a review of pharmacokinetics, efficacy and toxicity in patients with hematologic malignancies and solid tumors.Increased AURKA Gene Copy Number Correlates with Poor Prognosis and Predicts the Efficacy of High-dose Interferon Therapy in Acral Melanoma.
P2860
Q26748857-8EEA760C-CD7F-43CC-943C-4542A9773026Q26771371-FF6D8F00-F5E2-4E46-8FA5-3A93EE8BDD21Q26775723-0E90ACA3-02AC-4960-9483-1BAB4DBA5229Q26782270-3BC282CB-1B2D-4745-ACC6-3A8BA239CEDBQ26784060-A907F165-F543-4E04-BC88-9BCFD1D870E4Q33437992-9CF3AD93-E178-4776-89B9-80CBBEC7D668Q33438485-6EC8AEE0-340F-4833-9030-CDDAAD37C0BCQ33618929-B69B37F4-F0E6-4EF7-99B8-B4D15A4947D4Q35790720-D73DA403-D522-4654-8654-2ECF3F6F4C34Q37693690-29F7A6B8-0A33-432D-8869-C5148E34EEA6Q38581916-0828FDB1-F427-48D7-97BF-C3262BE51CC0Q38635909-FB3097C0-BF90-422E-BB0B-D08AF08650D4Q38756932-0308DD10-BBAA-4AAB-84A9-AF6FBC14FD18Q38782072-911EAD8E-AD50-4FE8-9295-994ED16C07ADQ38783162-E9C16606-A8C7-4FFD-BF10-F1A90A421A4AQ39063866-396F8EDE-C403-4E4F-87D7-A4198277B937Q39363642-AE9B5990-6673-4D02-A949-F0ABE19DFDC6Q40912134-03CEC1B0-2D41-422E-9BC5-2A9B59F67832Q47131247-AAF890B4-9B36-4D87-9200-F83B6600B6C2Q47147843-A324E13D-8333-4124-89E1-4EB496AC2EF4Q49421936-ECEC876B-2A3A-4752-B5AE-91957C424EC7Q50145911-57595E38-E4C5-4304-B023-10D7487D46DAQ51752158-2ED24398-E90C-4611-81E5-D5A2DABC71D2Q52718113-97C0C6AB-AF0C-488D-BA37-BD1C1C29182F
P2860
Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108.
description
2015 nî lūn-bûn
@nan
2015 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Phase II Intergroup Trial of A ...... Mycosis Fungoides: SWOG 1108.
@ast
Phase II Intergroup Trial of A ...... Mycosis Fungoides: SWOG 1108.
@en
type
label
Phase II Intergroup Trial of A ...... Mycosis Fungoides: SWOG 1108.
@ast
Phase II Intergroup Trial of A ...... Mycosis Fungoides: SWOG 1108.
@en
prefLabel
Phase II Intergroup Trial of A ...... Mycosis Fungoides: SWOG 1108.
@ast
Phase II Intergroup Trial of A ...... Mycosis Fungoides: SWOG 1108.
@en
P2093
P2860
P356
P1476
Phase II Intergroup Trial of A ...... d Mycosis Fungoides: SWOG 1108
@en
P2093
Brad S Kahl
Bruce D Cheson
Bryan D Huber
Catherine Spier
Christopher R Flowers
Daruka Mahadevan
Jonathan W Friedberg
Mansoor Ul Haq
Michael LeBlanc
P2860
P304
P356
10.1200/JCO.2014.60.6327
P407
P577
2015-06-15T00:00:00Z